NCT00583427

Sulodexide Treatment in Patients With Dense Deposit Disease

• Status: Withdrawn
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: University of Iowa · Academic / Other
• Sex: All
• Age: 5 Years – 20 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to see if a medicine called Sulodexide will help prevent or slow down the progression of Membranoproliferative Glomerulonephritis type II/Dense Deposit Disease. Sulodexide is not yet FDA approved and has not been studied in children. Study aim/hypotheses: to measure the efficacy of Sulodexide treatment in patients with the above disease/s.

Detailed description

Study subjects will be asked to take Sulodexide twice a day. The Sulodexide will be taken in addition to the regular medications the subject is on. There will be no change in these other medications. The subject will also be asked to have blood tests each month to follow kidney function. The frequency of these tests is the normal/standard frequency for persons with MPGN II/DDD and is neither increased nor decreased because of participation in this study. The study will occur over 6 months for each subject.

Conditions

• Dense Deposit Disease

Interventions

Type	Name	Description
DRUG	Sulodexide	200 mg per day in an oral gelcap form

Timeline

• Start date: 2007-12-01
• Primary completion: 2009-12-01
• Completion: 2009-12-01
• First posted: 2007-12-31
• Last updated: 2015-06-11

Locations

1 site across 1 country: United States